[{"id":"1356603e-b2dd-488c-b74a-f432af18b9a1","acronym":"DDRiver Solid Tumours 301","url":"https://clinicaltrials.gov/study/NCT04170153","created_at":"2021-06-11T21:52:37.231Z","updated_at":"2025-02-25T12:27:22.944Z","phase":"Phase 1","brief_title":"Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)","source_id_and_acronym":"NCT04170153 - DDRiver Solid Tumours 301","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" ARID1A • ATRX","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ARID1A • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • tuvusertib (M1774)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 161","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-24"},{"id":"a3ff3bf1-6fbc-4e00-b8e0-454d7fb78cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687136","created_at":"2023-01-18T15:59:53.342Z","updated_at":"2025-02-25T13:41:23.007Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors","source_id_and_acronym":"NCT05687136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"c28173c9-ac67-4f97-95aa-85bf990befb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04052555","created_at":"2021-01-18T19:52:14.840Z","updated_at":"2025-02-25T13:39:55.670Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04052555","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/24/2020","start_date":" 09/24/2020","primary_txt":" Primary completion: 11/20/2025","primary_completion_date":" 11/20/2025","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2025-02-21"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"d94f7980-52bd-4422-b97d-6ffc7470ef49","acronym":"NRG-GY031","url":"https://clinicaltrials.gov/study/NCT05950464","created_at":"2023-07-20T15:09:28.523Z","updated_at":"2025-02-25T14:42:14.385Z","phase":"Phase 1","brief_title":"Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer","source_id_and_acronym":"NCT05950464 - NRG-GY031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694 • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-14"},{"id":"611fb533-b8fd-4219-b354-66257bca25a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491942","created_at":"2021-01-18T21:34:47.482Z","updated_at":"2025-02-25T15:26:28.507Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","source_id_and_acronym":"NCT04491942","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/25/2021","start_date":" 08/25/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-10"},{"id":"6365efdc-854e-4454-ba10-f28f09a5a11b","acronym":"PEPN2112","url":"https://clinicaltrials.gov/study/NCT05071209","created_at":"2021-10-08T11:53:44.641Z","updated_at":"2025-02-25T17:01:24.348Z","phase":"Phase 1/2","brief_title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT05071209 - PEPN2112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3","pipe":" | ","alterations":" PAX3-FOXO1 fusion","tags":["BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PAX3-FOXO1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elimusertib (BAY 1895344)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 11/22/2025","study_completion_date":" 11/22/2025","last_update_posted":"2025-02-03"},{"id":"b72b0a64-54a8-4a42-8b82-b948a538ae47","acronym":"CAPRI","url":"https://clinicaltrials.gov/study/NCT03462342","created_at":"2021-01-18T17:04:00.829Z","updated_at":"2025-02-25T14:58:45.950Z","phase":"Phase 2","brief_title":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03462342 - CAPRI","lead_sponsor":"University of Pennsylvania","biomarkers":" HRD • BRCA • MUC16","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["HRD • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-31"},{"id":"9b1c2dc1-3b24-43f9-b184-70bf85aad83b","acronym":"NCI-2018-01648","url":"https://clinicaltrials.gov/study/NCT03682289","created_at":"2021-01-18T18:03:10.694Z","updated_at":"2025-02-25T15:07:56.671Z","phase":"Phase 2","brief_title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03682289 - NCI-2018-01648","lead_sponsor":"Rahul Aggarwal","biomarkers":" MSI • ATM • ARID1A • UGT1A1","pipe":" | ","alterations":" ATM mutation","tags":["MSI • ATM • ARID1A • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-01-28"},{"id":"1d507459-75e0-40d5-8168-57a298632833","acronym":"","url":"https://clinicaltrials.gov/study/NCT06732401","created_at":"2025-02-26T09:56:27.901Z","updated_at":"2025-02-26T09:56:27.901Z","phase":"Phase 3","brief_title":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06732401","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 630","initiation":"Initiation: 03/14/2025","start_date":" 03/14/2025","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-12-13"},{"id":"57e9cf07-fbd3-4b60-b000-b857b664ab20","acronym":"ATARI","url":"https://clinicaltrials.gov/study/NCT04065269","created_at":"2021-01-18T19:55:05.811Z","updated_at":"2025-02-25T15:08:44.072Z","phase":"Phase 2","brief_title":"ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss","source_id_and_acronym":"NCT04065269 - ATARI","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-07-11"},{"id":"fe022431-48d1-445d-8c8d-2321aa360be4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828082","created_at":"2023-04-25T14:03:34.885Z","updated_at":"2024-07-02T16:34:26.664Z","phase":"Phase 2","brief_title":"Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer","source_id_and_acronym":"NCT05828082","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SPOP • RAC1 • FDFT1 • MVD","pipe":" | ","alterations":" SPOP mutation","tags":["SPOP • RAC1 • FDFT1 • MVD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPOP mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/16/2023","start_date":" 10/16/2023","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 04/25/2025","study_completion_date":" 04/25/2025","last_update_posted":"2024-06-12"},{"id":"80611a75-8e50-4af0-8595-0b4412326e20","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576091","created_at":"2021-01-18T21:50:45.107Z","updated_at":"2024-07-02T16:34:37.303Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer","source_id_and_acronym":"NCT04576091","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • elimusertib (BAY 1895344) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 11/27/2024","primary_completion_date":" 11/27/2024","study_txt":" Completion: 11/27/2024","study_completion_date":" 11/27/2024","last_update_posted":"2024-06-07"},{"id":"122e5ddf-e06a-4539-a4fb-c6730d4e0338","acronym":"LATIFY","url":"https://clinicaltrials.gov/study/NCT05450692","created_at":"2022-07-11T12:56:21.525Z","updated_at":"2024-07-02T16:35:00.482Z","phase":"Phase 3","brief_title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","source_id_and_acronym":"NCT05450692 - LATIFY","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • docetaxel • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 563","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 05/12/2025","primary_completion_date":" 05/12/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-29"},{"id":"62aca2f8-43be-49bc-a240-562947c24958","acronym":"D5330C00004","url":"https://clinicaltrials.gov/study/NCT02264678","created_at":"2021-01-17T17:33:57.498Z","updated_at":"2024-07-02T16:35:02.492Z","phase":"Phase 1/2","brief_title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","source_id_and_acronym":"NCT02264678 - D5330C00004","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D","pipe":" | ","alterations":" HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation","tags":["HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • ceralasertib (AZD6738) • saruparib (AZD5305)"],"overall_status":"Recruiting","enrollment":" Enrollment 466","initiation":"Initiation: 10/31/2014","start_date":" 10/31/2014","primary_txt":" Primary completion: 08/05/2026","primary_completion_date":" 08/05/2026","study_txt":" Completion: 08/05/2026","study_completion_date":" 08/05/2026","last_update_posted":"2024-05-21"},{"id":"124724a9-c433-4ebd-b30a-756fba93c068","acronym":"LOTOS","url":"https://clinicaltrials.gov/study/NCT05941897","created_at":"2023-07-12T16:10:18.523Z","updated_at":"2024-07-02T16:35:02.636Z","phase":"Phase 2","brief_title":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","source_id_and_acronym":"NCT05941897 - LOTOS","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 07/29/2024","primary_completion_date":" 07/29/2024","study_txt":" Completion: 07/29/2025","study_completion_date":" 07/29/2025","last_update_posted":"2024-05-20"},{"id":"8a546e53-8398-4bf1-9589-03660de842b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03878095","created_at":"2021-01-18T19:07:08.982Z","updated_at":"2024-07-02T16:35:02.694Z","phase":"Phase 2","brief_title":"Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors","source_id_and_acronym":"NCT03878095","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • ceralasertib (AZD6738)"],"overall_status":"Suspended","enrollment":" Enrollment 50","initiation":"Initiation: 01/30/2020","start_date":" 01/30/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-17"},{"id":"f976983e-6e5c-40aa-ba00-71e22eb80e0e","acronym":"ATRIUM","url":"https://clinicaltrials.gov/study/NCT05338346","created_at":"2022-04-21T15:55:20.706Z","updated_at":"2024-07-02T16:35:08.451Z","phase":"Phase 1","brief_title":"A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies","source_id_and_acronym":"NCT05338346 - ATRIUM","lead_sponsor":"Antengene Discovery Limited","biomarkers":" BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" TP53 mutation • FANCF mutation","tags":["BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FANCF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATG-018"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-22"},{"id":"d42d31da-cd41-476a-aa36-97b674ad2ab1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04657068","created_at":"2021-01-19T20:41:48.099Z","updated_at":"2024-07-02T16:35:11.625Z","phase":"Phase 1/2","brief_title":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04657068","lead_sponsor":"Artios Pharma Ltd","biomarkers":" ATM • HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["ATM • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • irinotecan • alnodesertib (ART0380)"],"overall_status":"Recruiting","enrollment":" Enrollment 462","initiation":"Initiation: 12/13/2020","start_date":" 12/13/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-03"},{"id":"ae2fbbdf-1d9d-47eb-9888-dad360517475","acronym":"MATRIX","url":"https://clinicaltrials.gov/study/NCT05986071","created_at":"2023-08-14T15:09:50.416Z","updated_at":"2025-02-25T16:19:00.084Z","phase":"Phase 1/2","brief_title":"I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers","source_id_and_acronym":"NCT05986071 - MATRIX","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1","pipe":" | ","alterations":" HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation","tags":["HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • tuvusertib (M1774)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/15/2027","study_completion_date":" 10/15/2027","last_update_posted":"2024-03-29"},{"id":"74fab00e-e59b-494f-917f-dc80d3cf68bd","acronym":"NCI-2015-01779","url":"https://clinicaltrials.gov/study/NCT02589522","created_at":"2024-03-25T19:35:37.933Z","updated_at":"2024-07-02T16:35:12.957Z","phase":"Phase 1","brief_title":"Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors","source_id_and_acronym":"NCT02589522 - NCI-2015-01779","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 08/23/2021","primary_completion_date":" 08/23/2021","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-03-25"},{"id":"671d1c67-0f50-43c6-8185-9271e66bda87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05566574","created_at":"2022-10-04T13:56:50.895Z","updated_at":"2024-07-02T16:35:14.602Z","phase":"Phase 1/2","brief_title":"A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05566574","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ATM","pipe":" | ","alterations":" ATM mutation • ATM deletion","tags":["ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ATM deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-15"},{"id":"f6c20e60-2c54-4ca4-a32a-1818b76a2ae4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03770429","created_at":"2021-01-18T18:39:17.898Z","updated_at":"2025-02-25T15:08:09.884Z","phase":"Phase 1","brief_title":"AZD6738 for Patients With Progressive MDS or CMML","source_id_and_acronym":"NCT03770429","lead_sponsor":"Massachusetts General Hospital","biomarkers":" SF3B1 • SRSF2 • U2AF1 • ZRSR2","pipe":" | ","alterations":" SF3B1 mutation","tags":["SF3B1 • SRSF2 • U2AF1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 08/05/2019","start_date":" 08/05/2019","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-03-15"},{"id":"1511b518-b2d9-44d0-a52a-ddad9c414044","acronym":"CORONADO CLL","url":"https://clinicaltrials.gov/study/NCT05405309","created_at":"2022-06-06T13:56:17.349Z","updated_at":"2024-07-02T16:35:19.578Z","phase":"Phase 1/2","brief_title":"RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05405309 - CORONADO CLL","lead_sponsor":"University of Utah","biomarkers":" TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation","tags":["TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 09/23/2022","start_date":" 09/23/2022","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2027","study_completion_date":" 08/15/2027","last_update_posted":"2024-02-13"}]